Mary Kiconco

Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

Nicholas I. Paton, Cissy Kityo, Anne Hoppé et al. · New England Journal of Medicine · 2014 · 201 citations · Full text

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

Nicholas I. Paton, Cissy Kityo, Immaculate Nankya et al. · The Lancet HIV · 2017 · 79 citations · Full text

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, Cissy Kityo, Anne Hoppé et al. · The Lancet Infectious Diseases · 2017 · 41 citations · Full text

HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda

Cissy Kityo, Kim Sigaloff, T. Sonia Boender et al. · AIDS Research and Human Retroviruses · 2016 · 35 citations · Full text

Response to Antiretroviral Therapy of HIV Type 1-Infected Children in Urban and Rural Settings of Uganda

Victor Musiime, Joshua Kayiwa, Mary Kiconco et al. · AIDS Research and Human Retroviruses · 2012 · 25 citations